The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $27.54 in the last session, down -1.04% from day before closing price of $27.83. In other words, the price has decreased by -$1.04 from its previous closing price. On the day, 1.53 million shares were traded. RARE stock price reached its highest trading level at $28.21 during the session, while it also had its lowest trading level at $27.4.
Ratios:
We take a closer look at RARE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 5.84 whereas as Long-Term Debt/Eq ratio is at 5.34.
Goldman Upgraded its Neutral to Buy on June 06, 2024, whereas the target price for the stock was revised from $56 to $67.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 20 ’25 when Sanders Corazon (Corsee) D. sold 2,405 shares for $37.39 per share. The transaction valued at 89,923 led to the insider holds 15,344 shares of the business.
CORAZON D. SANDERS bought 2,405 shares of RARE for $89,923 on Jun 20 ’25. On May 05 ’25, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 520 shares for $39.24 each. As a result, the insider received 20,405 and left with 71,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2654073856 and an Enterprise Value of 3051632640. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.35 while its Price-to-Book (P/B) ratio in mrq is 17.51. Its current Enterprise Value per Revenue stands at 5.001 whereas that against EBITDA is -6.498.
Stock Price History:
The Beta on a monthly basis for RARE is 0.21, which has changed by -0.45893908 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -17.02%, while the 200-Day Moving Average is calculated to be -31.01%.
Shares Statistics:
According to the various share statistics, RARE traded on average about 1.84M shares per day over the past 3-months and 2065450 shares per day over the past 10 days. A total of 96.18M shares are outstanding, with a floating share count of 90.09M. Insiders hold about 6.52% of the company’s shares, while institutions hold 95.77% stake in the company. Shares short for RARE as of 1752537600 were 8801643 with a Short Ratio of 4.79, compared to 1749772800 on 6081072. Therefore, it implies a Short% of Shares Outstanding of 8801643 and a Short% of Float of 9.6499994.
Earnings Estimates
Currently, 12.0 analysts are dedicated to thoroughly evaluating and rating the performance of Ultragenyx Pharmaceutical Inc (RARE) in the stock market.The consensus estimate for the next quarter is -$1.12, with high estimates of -$0.8 and low estimates of -$1.54.
Analysts are recommending an EPS of between -$4.48 and -$5.66 for the fiscal current year, implying an average EPS of -$5.11. EPS for the following year is -$3.79, with 12.0 analysts recommending between -$1.06 and -$5.57.
Revenue Estimates
According to 16 analysts, the current quarter’s revenue is expected to be $166.27M. It ranges from a high estimate of $174M to a low estimate of $150M. As of the current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $139.49MFor the next quarter, 16 analysts are estimating revenue of $181.83M. There is a high estimate of $193.92M for the next quarter, whereas the lowest estimate is $152M.
A total of 20 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $668.55M, while the lowest revenue estimate was $589M, resulting in an average revenue estimate of $654.02M. In the same quarter a year ago, actual revenue was $560.23MBased on 20 analysts’ estimates, the company’s revenue will be $806M in the next fiscal year. The high estimate is $1.03B and the low estimate is $673.2M.
